Pharmaceutical company Jubilant Life Sciences reported a net profit of R44 crore for the three months from October-December 2010. The company’s net sales during the quarter stood at R867 crore.
“The company witnessed high volume and capacity utilisation in productssegment during the quarter and year to date across all products. There has been good growth in generics & APIs (active pharmaceutical ingredient) due to new product launches and market share gains,” said Shyam S Bhartia, chairman and managing director and Hari S Bhartia, co-chairman and managing director Jubilant Life Sciences.
Revenues from life science products stood at Rs 700 crore contributing 81% to the revenues of the company and registered a 13% growth during the quarter.
The company expects a robust growth in products segment in subsequent period due to strong order book position, new product launches in generics and APIs and capacity utilisation of proposed expansion to meet the growing demand of the customers in proprietary products and exclusive synthesis and nutrition ingredients.
The company, in its effort to create a focused life science entity, has demerged its agri and performance polymers business into a separate entity Jubilant Industries Ltd.